A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

Walter Reed Army Institute of Research (WRAIR)

Status: Completed

Conditions: Favism; Glucosephosphate Dehydrogenase Deficiency

Treatments: Drug: Primaquine

Study type: Interventional

Funder types: Other U.S. Federal agency

Identifiers

NCT00076323

WRAIR 992

G6PD

Details and patient eligibility

About

This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion:

• Normal clinical evaluation
• Willing and able to make all scheduled visits

Exclusion:

• pregnant or planning pregnancy
• Have taken any anti-malarial medication in past month
• Positive blood tests for HIV and specific types of hepatitis
• Allergic to primaquine

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)